Seqirus set to double flu vaccine production

24 August 2018

The US Food and Drug Administration’s (FDA) approval of Seqirus’ cell-based influenza vaccine manufacturing process at a US facility will allow the company to more than double production levels of Flucelvax Quadrivalent.

Seqirus, the second-largest vaccine company in the world and part of Australia’s CSL Limited (ASX: CSL), will be able to dramatically ramp up production for supply in the 2019/20 influenza season.

The announcement is the latest step forward for Seqirus, which has delivered on its pledge to reach profitability within just three years of being set up. The cell-based technology was acquired from Swiss pharma giant Novartis (NOVN: VX) in 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK